Evidence map›Paper›PMID 27838792›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017

Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).

B Hermann, N Lehners, M Brodhun, K Boden, A Hochhaus, M Kochanek, K Meckel, K Mayer, T Rachow, C Rieger and 6 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
    Article
  15. Review
  16. [Clinical features of influenza with plastic bronchitis in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Article
  17. AInternational journal of general medicine · 2020
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

B HermannLeibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany. eckidtdf@mailbox.alumni.tu-berlin.de.
N LehnersDepartment of Haematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.
M BrodhunMedizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
K BodenInstitut für Klinische Chemie und Laboratoriumsmedizin, University Hospital Jena, Jena, Germany.
A HochhausMedizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
M KochanekDepartment I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
K MeckelMedizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
K MayerMedizinische Klinik III, University Hospital Bonn, Bonn, Germany.
T RachowMedizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
C RiegerInternistische Lehrpraxis der Ludwig-Maximilians-Universität München, University of Munich, Munich, Germany.
E SchalkOtto-von-Guericke University Magdeburg, Medical Centre, Department of Haematology and Oncology, Magdeburg, Germany.
T WeberUniversity Hospital Halle, Halle, Germany.
A Schmeier-JürchottUniversity Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
P SchlattmannDepartment of Medical Statistics, Informatics and Documentation, University Hospital Jena, Jena, Germany.
D TeschnerUniversity Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
M von Lilienfeld-ToalLeibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany.
Jena University Hospital · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEHeidelberg University · DELeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DELudwig-Maximilians-Universität München · DEOtto-von-Guericke University Magdeburg · DEUniversity Hospital Bonn · DEUniversity Hospital Cologne · DEUniversity Hospital in Halle · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza virus infections (IVI) may pose a vital threat to immunocompromised patients such as those suffering from malignancies, but specific data on epidemiology and outcome in these patients are scarce. In this study, we collected data on patients with active cancer or with a history of cancer, presenting with documented IVI in eight centres in Germany. Two hundred and three patients were identified, suffering from haematological malignancies or solid tumours; 109 (54 %) patients had active malignant disease. Influenza A was detected in 155 (77 %) and Influenza B in 46 (23 %) of patients (genera not determined in two patients). Clinical symptoms were consistent with upper respiratory tract infection in 55/203 (27 %), influenza-like illness in 82/203 (40 %), and pneumonia in 67/203 (33 %). Anti-viral treatment with oseltamivir was received by 116/195 (59 %). Superinfections occurred in 37/203 (18 %), and admission on an intensive care unit was required in 26/203 (13 %). Seventeen patients (9 %) died. Independent risk factors for death were delayed diagnosis of IVI and bacterial or fungal superinfection, but not underlying malignancy or ongoing immunosuppression. In conclusion, patients with IVI show high rates of pneumonia and mortality. Early and rapid diagnosis is essential. The high rate of pneumonia and superinfections should be taken into account when managing IVI in these patients.

Indexed as

AgedAntiviral AgentsCritical CareFemaleGermanyHumansInfluenza A virusInfluenza B virusInfluenza, HumanMaleMiddle AgedNeoplasmsOseltamivirRisk FactorsSocietiesSuperinfectionAntiviral AgentsOseltamivir

Identifiers

PMID27838792
PMCPMC5309266
OpenAlexW2550104549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.